Usually for adults, administer one tablet (30mg of lansoprazole) orally once a day.
In duodenal ulcer, 30mg once daily for 4 weeks. In gastric ulcer and stomal ulcer, 30mg once daily for 8 weeks. In reflux esophagitis, 30mg once daily for 4-8 weeks. In Zollinger-Ellison syndrome, the dosage should be adjusted according to the patient's signs and symptoms.
Eradication of H. pylori: The following combinations have been shown to be effective over 7 days. Prevacid tablet 30mg twice daily plus two of the following antibiotics: amoxicillin 1g twice daily or metronidazole 400mg twice daily and clarithromycin 250-500mg twice daily. The best eradication results are obtained when clarithromycin is combined with either amoxicillin or metronidazole. When used in combination with the recommended antibiotics, PREVACID FDT is associated with H. pylori - eradication rates of up to 90%.
Acid related dyspepsia: 30 mg once daily for 2-4 weeks*.
Short term treatment of symptomatic GERD and Erosive Esophagitis (12-17 years): 30mg once daily for up to 8 weeks.
Treatment and prophylaxis of NSAID-associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued NSAID treatment: 15 or 30mg once daily for 4-8 weeks for treatment**. Prophylaxis: 15 or 30mg once daily.
Renal impairment: Dose adjustment is not required in patients with impaired renal function. However, a daily dosage of 30mg should not be exceeded.
Hepatic impairment: Patients with moderate or severe liver disease should be kept under regular supervision and a 50% reduction of the daily dose is recommended.
Elderly: Ulcer healing rates in elderly patients are similar to those in a younger age group. The incidence rates of adverse events and laboratory test abnormalities are also similar to those seen in younger patients. For elderly patients, dosage and administration of lansoprazole need not be altered for a particular indication.
* PREVACID FDT 30mg once daily for 2-4 weeks depending on the severity and persistence of symptoms. Patients who do not respond after 4 weeks, or who relapse shortly afterwards, should be investigated.
** Most patients will be healed after 4 weeks; for those patients not fully healed, a further 4 weeks treatment can be given. For patients at particular risk or with ulcers that may be difficult to heal, the higher dose and/or the longer treatment duration should be used.
PREVACID FDT should not be chewed. Place the tablet on the tongue and allow it to disintegrate, with or without water, until the particles can be swallowed. The tablet typically disintegrates in less than 1 minute.
Alternatively, for children or other patients who have difficulty swallowing tablets, PREVACID FDT can be delivered in two different ways.
PREVACID FDT - Oral Syringe: For administration via oral syringe, PREVACID FDT can be administered as follows: Place a 30mg tablet in oral syringe and draw up approximately 10 mL of water.
Shake gently to allow for quick dispersal.
After the tablet has dispersed, administer the contents within 15 minutes.
Refill the syringe with approximately 5mL of water, shake gently, and administer any remaining contents.
PREVACID FDT - Nasogastric Tube Administration (≥8 French): For administration via nasogastric tube, PREVACID FDT can be administered as follows: Place 30mg tablet in a syringe and draw up 10mL of water.
Shake gently to allow for a quick dispersal.
After the tablet has dispersed, inject through the nasogastric tube into the stomach within 15 minutes.
Refill the syringe with approximately 5mL of water, shake gently, and flush the nasogastric tube.